The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.

@article{Kubo2014TheJI,
  title={The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.},
  author={Satoshi Kubo and Kunihiro Yamaoka and Masahiro Kondo and Kaoru Yamagata and Jidong Zhao and Shigeru Iwata and Yoshiya Tanaka},
  journal={Annals of the rheumatic diseases},
  year={2014},
  volume={73 12},
  pages={2192-8}
}
OBJECTIVE Tofacitinib, which is a Janus kinase (JAK) inhibitor, has shown clinical effects in the treatment of rheumatoid arthritis. JAKs are important kinases in lymphocyte differentiation; however, their function in dendritic cells (DCs) is unknown. In this study, the function of JAKs in DCs was investigated with tofacitinib. METHODS The effects of tofacitinib on the maturation of human monocyte-derived DCs induced by lipopolysaccharide (LPS) stimulation were investigated. In addition, its… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…